Another way forward is the reverse of the one I've been proposing for some time now: a very broad out-licensing of the high impacts, to fund development of the low-impacts.
If the Servier trial establishes an effective dosage range that is far from the dosage range that induces seizures, such a deal could happen.
The advantage of relinquishing high-impact IP to develop low-impact IP is that the low-impacts are closer to the clinic, and hence could generate profits sooner. Also, seizure risk is much lower, so low impacts have a better chance of getting FDA approval.
I don't know how they'll get there, but I think that somehow corx will find its way to profitability. Unfortunately, it is going to be still more difficult to get there without wiping out current stock-holders in the process.
News 
Market Data 
Discover 
AI
